These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27879129)

  • 1. On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach.
    Ledzewicz U; Wang S; Schattler H; Andre N; Heng MA; Pasquier E
    Math Biosci Eng; 2017 Feb; 14(1):217-235. PubMed ID: 27879129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?
    Ledzewicz U; Schättler H
    Cancer Lett; 2017 Aug; 401():74-80. PubMed ID: 28323033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal control of a mathematical model for cancer chemotherapy under tumor heterogeneity.
    Wang S; Schattler H
    Math Biosci Eng; 2016 Dec; 13(6):1223-1240. PubMed ID: 27775377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
    Hida K; Kikuchi H; Maishi N; Hida Y
    Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of an in vitro chemotherapy to avoid resistant tumours.
    Carrère C
    J Theor Biol; 2017 Jan; 413():24-33. PubMed ID: 27864095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.
    Hamis S; Nithiarasu P; Powathil GG
    J Theor Biol; 2018 Oct; 454():253-267. PubMed ID: 29909142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive therapy.
    Gatenby RA; Silva AS; Gillies RJ; Frieden BR
    Cancer Res; 2009 Jun; 69(11):4894-903. PubMed ID: 19487300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calculated resistance in cancer.
    Sawyers CL
    Nat Med; 2005 Aug; 11(8):824-5. PubMed ID: 16079872
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics.
    Ledzewicz U; Naghnaeian M; Schättler H
    J Math Biol; 2012 Feb; 64(3):557-77. PubMed ID: 21553244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs.
    Usher JR; Henderson D
    IMA J Math Appl Med Biol; 1996 Jun; 13(2):99-126. PubMed ID: 8671582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical Modelling and Analysis of the Tumor Treatment Regimens with Pulsed Immunotherapy and Chemotherapy.
    Pang L; Shen L; Zhao Z
    Comput Math Methods Med; 2016; 2016():6260474. PubMed ID: 26997972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs.
    Yoon N; Vander Velde R; Marusyk A; Scott JG
    Bull Math Biol; 2018 Jul; 80(7):1776-1809. PubMed ID: 29736596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
    Kareva I
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1997 Dec; 14(4):283-303. PubMed ID: 9415996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.
    Sameen S; Barbuti R; Milazzo P; Cerone A; Del Re M; Danesi R
    J Theor Biol; 2016 Jan; 389():263-73. PubMed ID: 26551156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1995; 12(1):55-69. PubMed ID: 7594878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of mathematical modeling in protocol formulation in cancer chemotherapy.
    Coldman AJ; Goldie JH
    Cancer Treat Rep; 1985 Oct; 69(10):1041-8. PubMed ID: 2412691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to metronomic chemotherapy and ways to overcome it.
    Riesco-Martinez M; Parra K; Saluja R; Francia G; Emmenegger U
    Cancer Lett; 2017 Aug; 400():311-318. PubMed ID: 28259819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.